Evonetix Secures $24 Million for Gene Synthesis Innovation
Evonetix, an innovative company specializing in synthetic biology, is based in the vibrant city of Cambridge, UK. The company has made headlines recently by successfully raising an additional $24 million in its Series B funding round, bringing the total amount raised in this round to an impressive $54 million. This latest round was spearheaded by Foresite Capital, with significant participation from several other notable investors including Molten Ventures, Morningside, DCVC, Cambridge Consultants, Civilization Ventures, and Providence. These funds will play a crucial role in the company's ongoing efforts to develop its semiconductor chips to a commercial scale and enhance its gene assembly capabilities.
Under the leadership of CEO Colin McCracken, Evonetix has introduced a proprietary synthesis process that employs a cutting-edge silicon chip designed to specifically control the synthesis of DNA.
This chip operates through a unique system that utilizes thousands of independent thermally controlled reaction sites—or 'pixels'—allowing for the precise assembly of long, accurate DNA sequences directly on the chip's surface via its patented Binary Assembly process. The sophistication of this technology enables Evonetix to synthesize thousands of genetic sequences simultaneously on a single chip, dramatically reducing the time required to create complex libraries and assemble lengthy DNA strands from weeks to just a few days. This efficiency is poised to significantly accelerate research in the burgeoning field of synthetic biology.
In response to this latest funding news, Colin McCracken expressed his enthusiasm by stating, “This substantial investment round demonstrates continued confidence in the progress of our technical development and its potential to revolutionise the accessibility of gene synthesis. Evonetix is in a very exciting phase, having recently opened our early access program. This investment will support us as we execute on our commercial strategy to put benchtop gene synthesis in the hands of users.” The implications of this investment and technological advancement could be profound, opening new avenues for researchers and innovators in synthetic biology, and ultimately transforming how genetic engineering and DNA synthesis are approached in laboratories around the world.
They've invested in Evonetix
Get to know these Biotech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
 Foresite Capital( ) | Evonetix | |||
MAIA TechnologyModo EnergyPolyModels HubDuel+10 | ||||
 DCVC( ) | Quantum MotionRelation TherapeuticsRecycleye | |||
 Civilization Ventures( ) | Oxford Cancer Analytics | |||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK